Stock Track | Harrow Health Soars Nearly 6% Pre-Market on CMS Approval for Triesence Reimbursement

Stock Track03-24 13:42

Harrow Health Inc (HROW) stock is soaring 5.95% in pre-market trading on Monday, following a significant regulatory development for its product Triesence. The company received approval from the Centers for Medicare & Medicaid Services (CMS) for Transitional Pass-Through Status for Triesence 40 mg/ml, boosting investor confidence in the pharmaceutical firm's future prospects.

The CMS approval grants Triesence, Harrow's triamcinolone acetonide injectable suspension, a Transitional Pass-Through Status. This designation is crucial for new medical devices, drugs, and biologicals that apply for separate Medicare payments, allowing for adequate reimbursement while the product establishes its place in the market. The approval signifies recognition of Triesence's potential value in patient care and could lead to increased adoption in healthcare settings.

Furthermore, Harrow announced that Triesence will be eligible for separate reimbursement in Ambulatory Surgery Center (ASC) and Hospital Outpatient Department (HOPD) settings starting from April 2025. This separate reimbursement status could potentially drive higher usage of Triesence in these healthcare facilities, potentially leading to increased sales and revenue for Harrow Health. Investors appear to be reacting positively to these developments, anticipating a positive impact on the company's financial performance in the coming years.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1142135742?lang=en_US&edition=full_marsco","thumbnail":"","is_english":true,"pubTime":"2025-03-24 21:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1142135742","market":"hk","top_or_hot":-1,"title":"Stock Track | Harrow Health Soars Nearly 6% Pre-Market on CMS Approval for Triesence Reimbursement","media":"Stock Track","content":"<p>Harrow Health Inc (HROW) stock is soaring 5.95% in pre-market trading on Monday, following a significant regulatory development for its product Triesence. The company received approval from the Centers for Medicare & Medicaid Services (CMS) for Transitional Pass-Through Status for Triesence 40 mg/ml, boosting investor confidence in the pharmaceutical firm's future prospects.</p>\n\n<p>The CMS approval grants Triesence, Harrow's triamcinolone acetonide injectable suspension, a Transitional Pass-Through Status. This designation is crucial for new medical devices, drugs, and biologicals that apply for separate Medicare payments, allowing for adequate reimbursement while the product establishes its place in the market. The approval signifies recognition of Triesence's potential value in patient care and could lead to increased adoption in healthcare settings.</p>\n\n<p>Furthermore, Harrow announced that Triesence will be eligible for separate reimbursement in Ambulatory Surgery Center (ASC) and Hospital Outpatient Department (HOPD) settings starting from April 2025. This separate reimbursement status could potentially drive higher usage of Triesence in these healthcare facilities, potentially leading to increased sales and revenue for Harrow Health. Investors appear to be reacting positively to these developments, anticipating a positive impact on the company's financial performance in the coming years.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Harrow Health Soars Nearly 6% Pre-Market on CMS Approval for Triesence Reimbursement</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Harrow Health Soars Nearly 6% Pre-Market on CMS Approval for Triesence Reimbursement\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-03-24 21:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Harrow Health Inc (HROW) stock is soaring 5.95% in pre-market trading on Monday, following a significant regulatory development for its product Triesence. The company received approval from the Centers for Medicare & Medicaid Services (CMS) for Transitional Pass-Through Status for Triesence 40 mg/ml, boosting investor confidence in the pharmaceutical firm's future prospects.</p>\n\n<p>The CMS approval grants Triesence, Harrow's triamcinolone acetonide injectable suspension, a Transitional Pass-Through Status. This designation is crucial for new medical devices, drugs, and biologicals that apply for separate Medicare payments, allowing for adequate reimbursement while the product establishes its place in the market. The approval signifies recognition of Triesence's potential value in patient care and could lead to increased adoption in healthcare settings.</p>\n\n<p>Furthermore, Harrow announced that Triesence will be eligible for separate reimbursement in Ambulatory Surgery Center (ASC) and Hospital Outpatient Department (HOPD) settings starting from April 2025. This separate reimbursement status could potentially drive higher usage of Triesence in these healthcare facilities, potentially leading to increased sales and revenue for Harrow Health. Investors appear to be reacting positively to these developments, anticipating a positive impact on the company's financial performance in the coming years.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HROW","symbol_name":"Harrow Health Inc","start_time":0,"source_url":"","article_id":"1142135742","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1142135742","pubTimestamp":1742823746,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Harrow Health Inc  stock is soaring 5.95% in pre-market trading on Monday, following a significant regulatory development for its product Triesence. The company received approval from the Centers for Medicare & Medicaid Services  for Transitional Pass-Through Status for Triesence 40 mg/ml, boosting investor confidence in the pharmaceutical firm's future prospects.The CMS approval grants Triesence, Harrow's triamcinolone acetonide injectable suspension, a Transitional Pass-Through Status. This de","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HROW":"Harrow Health Inc"},"translate_title":"CMS批准Triesence报销后，Harrow Health盘前股价飙升近6%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HROW":1},"content_text":"Harrow Health Inc (HROW) stock is soaring 5.95% in pre-market trading on Monday, following a significant regulatory development for its product Triesence. The company received approval from the Centers for Medicare & Medicaid Services (CMS) for Transitional Pass-Through Status for Triesence 40 mg/ml, boosting investor confidence in the pharmaceutical firm's future prospects.\nThe CMS approval grants Triesence, Harrow's triamcinolone acetonide injectable suspension, a Transitional Pass-Through Status. This designation is crucial for new medical devices, drugs, and biologicals that apply for separate Medicare payments, allowing for adequate reimbursement while the product establishes its place in the market. The approval signifies recognition of Triesence's potential value in patient care and could lead to increased adoption in healthcare settings.\nFurthermore, Harrow announced that Triesence will be eligible for separate reimbursement in Ambulatory Surgery Center (ASC) and Hospital Outpatient Department (HOPD) settings starting from April 2025. This separate reimbursement status could potentially drive higher usage of Triesence in these healthcare facilities, potentially leading to increased sales and revenue for Harrow Health. Investors appear to be reacting positively to these developments, anticipating a positive impact on the company's financial performance in the coming years.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1142135742"}